China SXT Pharmaceuticals
SXTC
4 hedge funds and large institutions have $131K invested in China SXT Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 6 closing their positions.
0.07% more ownership
Funds ownership: 0% → 0.07% (+0.07%)
50% less funds holding
Funds holding: 8 → 4 (-4)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
75% less capital invested
Capital invested by funds: $524K → $131K (-$393K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.01M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$205 |
| 3 |
CIAM
Caitong International Asset Management
Hong Kong
|
+$26 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$241K |
| 2 |
Invesco
Atlanta,
Georgia
|
-$137K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$85.9K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$36.4K |
| 5 |
VF
Virtu Financial
New York
|
-$20K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $131K | +$2.01M | +78,170 | New |
|
2
UBS Group
Zurich,
Switzerland
| $2 | – | – | – |
|
|
CIAM
3
Caitong International Asset Management
Hong Kong
| $2 | +$26 | +1 | New |
|
|
4
Citadel Advisors
Miami,
Florida
| – | -$241K | -1,004 | Closed |
|
|
5
Invesco
Atlanta,
Georgia
| – | -$137K | -569 | Closed |
|
|
6
Geode Capital Management
Boston,
Massachusetts
| – | -$85.9K | -358 | Closed |
|
|
XT
7
XTX Topco
George Town,
Cayman Islands
| – | -$36.4K | -152 | Closed |
|
|
VF
8
Virtu Financial
New York
| – | -$20K | -82 | Closed |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| – | -$2.92K | -12 | Closed |
|
|
10
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$205 | +8 | +160% |
|
SXTC Hedge Fund Activity: Q1 2026 in Review
4 of the 8,150 institutional investors tracked by Wall St. Rank reported a position in China SXT Pharmaceuticals (SXTC) for Q1 2026, worth a combined $131K — down 75% from $524K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of SXTC and 2 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $2.01M. The largest seller was Citadel Advisors, exiting entirely with an estimated $241K sold.
- 4 institutional investors held China SXT Pharmaceuticals (SXTC) as of Q1 2026, down from 8 in Q4 2025.
- Funds reported $131K of China SXT Pharmaceuticals stock for Q1 2026, down 75% quarter-over-quarter.
- 2 funds opened new China SXT Pharmaceuticals positions in Q1 2026 and 6 closed out, a net change of -4 holders.
- The largest China SXT Pharmaceuticals buyer in Q1 2026 was Sabby Management, an estimated $2.01M added.
- The largest China SXT Pharmaceuticals seller in Q1 2026 was Citadel Advisors, an estimated $241K sold.
Based on aggregated 13F filings for Q1 2026.